Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Inhalational Drug Delivery in Pulmonary Aspergillosis

Volumen 36, Ausgabe 3, 2019, pp. 183-217
DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025781
Get accessGet access

ABSTRAKT

Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.

REFERENZIERT VON
  1. Kaur Ranjot, Kaushik Anupama, Singh Kamalinder K., Katare O. P., Singh Bhupinder, An Efficient and Cost-Effective Nose-Only Inhalational Chamber for Rodents: Design, Optimization and Validation, AAPS PharmSciTech, 21, 3, 2020. Crossref

  2. Cheng Shen Nam, Tan Zhi Guang, Pandey Manisha, Srichana Teerapol, Pichika Mallikarjuna Rao, Gorain Bapi, Choudhury Hira, A Critical Review on Emerging Trends in Dry Powder Inhaler Formulation for the Treatment of Pulmonary Aspergillosis, Pharmaceutics, 12, 12, 2020. Crossref

  3. Cosio Terenzio, Gaziano Roberta, Zuccari Guendalina, Costanza Gaetana, Grelli Sandro, Di Francesco Paolo, Bianchi Luca, Campione Elena, Retinoids in Fungal Infections: From Bench to Bedside, Pharmaceuticals, 14, 10, 2021. Crossref

  4. Kaur Ranjot, Dennison Sarah R., Burrow Andrea J., Rudramurthy Shivaprakash M., Swami Rajan, Gorki Varun, Katare O. P., Kaushik Anupama, Singh Bhupinder, Singh Kamalinder K., Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention, Journal of Nanobiotechnology, 19, 1, 2021. Crossref

  5. Kaur Ranjot, Saini Sumant, Patel Asha, Sharma Teenu, Kaur Ripandeep, Katare O. P, Singh Bhupinder, Developing a Validated HPLC Method for Quantification of Ceftazidime Employing Analytical Quality by Design and Monte Carlo Simulations, Journal of AOAC INTERNATIONAL, 104, 3, 2021. Crossref

  6. Kaur Ranjot, Dennison Sarah R, Rudramurthy Shivaprakash M, Katare O P, Sharma Teenu, Singh Bhupinder, Singh Kamalinder K, Aerosolizable Lipid-Nanovesicles Encapsulating Voriconazole Effectively Permeate Pulmonary Barriers and Target Lung Cells, Frontiers in Pharmacology, 12, 2022. Crossref

  7. Ito Kazuhiro, Inhaled antifungal therapy: benefits, challenges, and clinical applications, Expert Opinion on Drug Delivery, 19, 7, 2022. Crossref

  8. K Deepasree, Venugopal Subhashree, Therapeutic potential of selenium nanoparticles, Frontiers in Nanotechnology, 4, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain